Načítá se...
Cabozantinib and apixaban: an hitherto unreported interaction
The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment with possible drug-drug interaction with other drugs such as oral anticoagulant. We descri...
Uloženo v:
| Vydáno v: | Exp Hematol Oncol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6737677/ https://ncbi.nlm.nih.gov/pubmed/31528502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0146-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|